 |
|
Correlation of PD-L1 Expression Tested by 22C3 and SP263 in Non-Small Cell Lung Cancer and Its Prognostic Effect on
Taehee Kim, Yoon Jin Cha, Yoon Soo Chang
Tuberc Respir Dis. 2020;83(1):51-60. Published online 2019 Aug 31 DOI: https://doi.org/10.4046/trd.2019.0026
|
|
Citations to this article as recorded by
 Research Progress of EGFR-TKIs Resistance and PD-L1 Expression in EGFR-Mutant Non-Small Cell Lung Cancer
雅婷 温
Advances in Clinical Medicine.2024; 14(01): 183. CrossRef Association of PD-L1 expression and clinical outcomes in ROS1 - rearranged advanced non-small cell lung cancer treated with crizotinib
Huixian Zhang, Ziheng Zhang, Ningning Yan, Xingya Li
Frontiers in Oncology.2024;[Epub] CrossRef Factors correlating the expression of PD-L1
Fang Lu, Ernuo Wang, Haiquan Liu
BMC Cancer.2024;[Epub] CrossRef Effect of BIM expression on the prognostic value of PD-L1 in advanced non-small cell lung cancer patients treated with EGFR-TKIs
Chang-Yao Chu, Chien-Yu Lin, Chien-Chung Lin, Chien-Feng Li, Shang-Yin Wu, Jeng-Shiuan Tsai, Szu-Chun Yang, Chian-Wei Chen, Chia-Yin Lin, Chao-Chun Chang, Yi-Ting Yen, Yau-Lin Tseng, Po-Lan Su, Wu-Chou Su
Scientific Reports.2023;[Epub] CrossRef New targeted therapies for non-small cell lung cancer
Eun Hye Lee, Se Hyun Kwak, Chi Young Kim, Hye Ran Gwon, Eun Young Kim, Yoon Soo Chang
Journal of the Korean Medical Association.2023; 66(3): 180. CrossRef Influence of PD‐L1 expression on the efficacy of EGFR‐TKIs in EGFR‐mutant non‐small cell lung cancer
Si‐Yu Lei, Hai‐Yan Xu, Hong‐Shuai Li, Ya‐Ning Yang, Fei Xu, Jun‐Ling Li, Zhi‐Jie Wang, Pu‐Yuan Xing, Xue‐Zhi Hao, Yan Wang
Thoracic Cancer.2023; 14(24): 2327. CrossRef A phase Ib trial of pembrolizumab plus paclitaxel or flat-dose capecitabine in 1st/2nd line metastatic triple-negative breast cancer
David B. Page, Joanna Pucilowska, Brie Chun, Isaac Kim, Katherine Sanchez, Nicole Moxon, Staci Mellinger, Yaping Wu, Yoshinobu Koguchi, Valerie Conrad, William L. Redmond, Maritza Martel, Zhaoyu Sun, Mary B. Campbell, Alison Conlin, Anupama Acheson, Reva
npj Breast Cancer.2023;[Epub] CrossRef Development of A Nanostructured Lipid Carrier-Based Drug Delivery Strategy for Apigenin: Experimental Design Based on CCD-RSM and Evaluation against NSCLC In Vitro
Xiaoxue Wang, Jinli Liu, Yufei Ma, Xinyu Cui, Cong Chen, Guowei Zhu, Yue Sun, Lei Tong
Molecules.2023; 28(18): 6668. CrossRef Programmed death ligand 1 protein expression is positively correlated with the solid predominant subtype, high MIB-1 labeling index, and p53 expression and negatively correlated with epidermal growth factor receptor mutations in lung adenocarcinoma
Naoki Yanagawa, Satoshi Shiono, Makoto Endo, Shin-ya Ogata, Noriyuki Yamada, Ryo Sugimoto, Mitsumasa Osakabe, Noriyuki Uesugi, Tamotsu Sugai
Human Pathology.2021; 108: 12. CrossRef Association Between PDL1 Genetic Variation and Efficacy of Apatinib Monotherapy in Patients with Previously Treated Advanced NSCLC: A Real-World Retrospective Study
Wenxia Hu, Bin Li, Nan Geng, Xin He, Hui Ge, Ping Wang, Cuimin Ding
International Journal of General Medicine.2021; Volume 14: 2703. CrossRef The predictive and prognostic effects of PD-L1 expression on TKI treatment and survival of EGFR-mutant NSCLC
Bo Lan, Yongfang Wang, Jingni Wu, Kai Wang, Pingli Wang
Medicine.2021; 100(34): e27038. CrossRef Primary Resistance to Immune Checkpoint Blockade in an STK11/TP53/KRAS-Mutant Lung Adenocarcinoma with High PD-L1 Expression Won Gun Kwack, So Youn Shin, Seung Hyeun Lee
OncoTargets and Therapy.2020; Volume 13: 8901. CrossRef Smoking, as a Death Messenger
Hye Jung Park
Tuberculosis and Respiratory Diseases.2020; 83(4): 324. CrossRef
|